吉非替尼治疗晚期肺腺癌疗效观察  

The Treatment For Clinical Observation on Treatment of Advanced Lung Adenocarcinoma

作　　者：王俊杰[1] 蔡敏[2] 

机构地区：[1]包钢医院心胸外科,内蒙古包头014010 [2]包头医学院第一附属医院,内蒙古包头014010

出　　处：《内蒙古医学杂志》2015年第8期947-949,共3页Inner Mongolia Medical Journal

摘　　要：目的研究吉非替尼对表皮生长因子受体(EGFR)突变的晚期肺腺癌临床效果。方法选取我院胸外科及肿瘤科收治晚期对表皮生长因子受体(EGFR)突变肺腺癌肺癌患者16例。所有患者均口服吉非替尼进行治疗。结果 16例患者中完全缓解10例,部分缓解4例,好转1例,无效1例,所有患者总有效率为93.8%。药物不良反应多数为皮疹和腹泻,而且均较轻。结论使用吉非替尼靶向治疗晚期对EGFR突变肺腺癌患者有较明显的抗肿瘤作用且改善了患者生活质量,服用方便,依从性好。Objective To investigate gefitinib epidermal growth factor receptor（EGFR）mutations in advanced lung cancer clinical effect.Methods In our hospital thoracic surgery and oncology admitted late on epidermal growth factor receptor（EGFR）mutations in 16 patients with lung cancer.All patients underwent oral gefitinib.Results 16 patients 10 cases of complete remission,partial remission in4 cases,improved in1 case,Invalid 1 case,All patients total effective rate of 93.8%,Most adverse drug reactions were rash and diarrhea,and were mild.Conclusion Gefitinib targeted therapy of advanced lung cancer patients with EGFR mutations have a more significant anti-tumor effect and improve the quality of life,easy to take and better compliance.

关 键 词：肺腺癌 晚期 吉非替尼 

分 类 号：R734.2[医药卫生—肿瘤]